| abstract |
(57) [Summary]nThe present invention provides tropane-derived monoamine neurotransmitter reuptake inhibitors that exhibit selectivity for either serotonin or dopamine transporters as expected, pharmaceutical compositions thereof, and methods of use thereof. Serotonin-selective reuptake inhibitors are particularly useful for treating neurological disorders associated with the serotonergic nervous system of the brain, such as depression, and the side effects are significantly reduced. Dopamine selective reuptake inhibitors are particularly useful for treating disorders related to dopamine reuptake and / or acetylcholine release. |